CD38 and cancer: On the basis of these unique characteristics of quiescence and high clonogenic potential, the authors contemplated the possibility of CPCs representing a cancer stem cell-like population in myeloma.1 These findings imply that monoclonal antibodies against surface markers like CD38 might not be effective against CPCs.